Symptoms and pulmonary function in asthma  by Alcock, S.M. et al.
RESPIRATORY MEDICINE (1998) 92, 849-857 
Symptoms and pulmonary function in asthma 
S. M. ALCOCK, M. MAMUN,, R. J. PRESCOTT+ AND C. K. CONNOLLY" 
Departments of Medicine, Darlington Memorial Hospital NHS Trust 
“University of Newcastle upon Tyne, 
‘Medical Statistics Unit, University of Edinburgh 
The relationship between symptoms and pulmonary function in asthma is important if the latter is to be held 
relevant to management guidelines and their audit. Associations between reported symptoms, pulmonary function 
and therapy were studied in 824 asthmatics (mean FEV, 75.4% predicted; best FEV, 84.6% predicted; and 
actual/best peak flow (PEF) 87.5%). Bronchodilator usage (reflecting symptomatic wheeze) was evenly distributed up 
to eight times daily; 22.5% of subjects had nocturnal disturbance and 46.3% persistent daytime symptoms. The 
univariate relationships between symptoms and function were generally closer with best rather than actual/best. 
They were further explored using quintiles of function. Symptoms were consistently less as best function increased, 
but were highly significantly greater in the fifth than in the third and fourth quintiles of actual/best FEV,. There was 
a trend to a similar U-shaped relationship of actual/best PEF with nocturnal disturbance and daytime symptoms. 
Best function is a good determinant of expected symptom load in an asthmatic population. Below 85% actual/best 
function reflects the prevalence of symptoms. In asymptomatic patients a level of at least 85-90% is a useful check 
of physiological control but will not exclude some symptomatic patients, irrespective of best function. 
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Introduction 
Published guidelines suggest that measurements of pulmon- 
ary function should be incorporated in the management of 
chronic asthma (1,2). Assessments should be made in the 
light of best function (3). If guidelines and audit of outcome 
are to be relevant to management, particularly from the 
patient’s point of view, then any measure of pulmonary 
function is likely to be most useful if it bears some 
relationship to symptoms. However, the relationships 
between symptoms and measurements of pulmonary func- 
tion in patients with airway obstruction are difficult to 
establish and, even with the best objective measures of 
performance, pulmonary function explains less than 50% of 
between-patients variance in symptom scores (4,5). 
In the Darlington and Northallerton long-term asthma 
study (DANLAST) we have determined best function 
on optimal therapy in all subjects and assessed control at 
the time of attendance by the actual function observed 
divided by the best obtainable (6). In cross-sectional 
models, we observed a steep decline in best function with 
increasing therapeutic step and that therapy may be 
adjusted to obtain similar levels of actual/best function at 
each therapeutic step (7). Similar results were seen in an 
audit study involving several centres (8). 
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In the tenth-year review of DANLAST, all current 
subjects were reviewed and new patients entered. In the 
preliminary longitudinal analysis, poor best function pre- 
dicted mortality, but after multivariate analysis, actual/best 
function was a poor predictor of long-term outcome (9). 
We also recorded current symptoms in both the subjects 
under review and the new entrants. As we confirmed that 
best function was worse in those on a higher therapeutic 
step, we anticipated an association between symptoms, 
particularly those with a global connotation, and best 
function, but also anticipated a strong relationship between 
actual/best function and current symptoms. In order to test 
this hypothesis, we looked at the relationship between 
reported symptoms, pulmonary function (expressed as best 
and actual/best), and therapy in all participants. 
Methods 
SUBJECTS 
All patients aged over 18, attending with a clinical diagnosis 
of asthma at hospital clinics or privately in the former 
Darlington and Northallerton Health Districts of the 
National Health Service were included, subject to the 
following criteria: 
A clinical diagnosis of asthma; 
Demonstration of reversibility of peak flow (PEF) by 
215% to 22001min-’ on more than one occasion at 
some time in the past; 
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TABLE 1. Details of subjects and their pulmonary function 
Male Female All 
n 405 419 824 
Age (years) (SD) 55.8 (15.01) 54.2 (16.4) 55.0 (158) 
Atopic (%) 186 (45.9) 188 (44.9) 374 (45.3) 
Current smokers (%) 30 (7.4) 32 (7.6) 62 (7.5) 
Never smokers (%) 119 (29.3) 213 (50.8) 332 (40.3) 
Best PEF % (SD) 86.3 (18.7) 102.3 (21.0) 94.5 (21.4) 
Actual/best PEF % (SD) 87.4 (12.1) 87.7 (12.3) 87.5 (12.1) 
Best FEV, % (SD) 80.4 (27.8) 88.4 (24.3) 84.6 (26.3) 
Actual/best FEV, % (SD) 90.0 (11.6) 89.3 (11.6) 89.6 (11.6) 
TABLE 2. Pulmonary function showing mean and interquintile values 
Interquintile values 
rl Mean SD 1 2 3 4 
Actual FEV, 751 75.4 26.8 49.1 68.3 82.3 98.3 
Best FEV, 7.51 84.6 28.6 60.3 79.0 92.0 107.3 
Actual/best FEV, 751 89.6 11.4 81.0 88.8 94.2 98.2 
109.6 
Actual PEF 815 83.5 24.1 60.5 79.3 90.5 103.5 
Best PEF 824 94.5 21.4 76.1 90.4 101.0 111.9 
Actual/best PEF 815 87.5 12.1 78.4 87.7 93.3 98.0 
TABLE 3. The therapeutic steps of the subjects, showing the percentage distribution of those on 
satisfactory therapy. (Subjects on booster steroids at attendance are classified by their normal 
preventative treatment.) 
Male (n =405) Female (n=419) All (n = 824) 
Therapy n (% satisfactory) n (% satisfactory) (% satisfactory) 
Bronchodilator only/DSG 39 (10.4) 38 (9.7) 77 (10.1) 
Inhaled steroids 1800 pg 136 (36.2) 167 (42.3) 303 (39.6) 
Inhaled steroids 800-1000,~g 119 (31.7) 85 (21.8) 204 (26.6) 
Inhaled steroids > 1000 fig 52 (13.9) 66 (16.9) 118 (15.4) 
Oral steroids 29 (7.7) 35 (9.5) 64 (8.4) 
All satisfactory 375 391 766 
Not satisfactory 30 (7.4)* 28 (6.7)* 58 (7.0)* 
All patients 405 419 824 
*Percentage of all subjects. 
Previous attendance of at least 1 year. in all subjects, whether current clinic attenders, special 
The study started in 1983, with reviews in 1988-1989 and attenders or new entrants. 
199331994. New subjects satisfying the above criteria were 
entered at each review. Patients who had been discharged HISTORY 
or lost to follow-up in the intervening period were offered a 
special attendance solely for the study. This report includes A structured history was taken, which included the 
the findings recorded during the tenth year of the study following: 
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FIG. 1. The distribution of symptom scores: (a) disturbed 
nights; (b) bronchodilator usage; (c) daily activity score. 
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(a) Bronchodilator usage: average frequency (occasions) of 
short-acting bronchodilator use per 24 hours over the 
previous 4 weeks 
(b) Nocturnal disturbance: average number of nights dis- 
turbed per week by respiratory symptoms over the 
previous 4 weeks 
(c) Daily activity score: O=normal; 1 =coped despite symp- 
toms; 2=activities, games etc. restricted because of 
symptoms; 3 =unable to do normal household activities 
because of symptoms; 4=severely disabled (e.g. assist- 
ance required with dressing, wheelchair, etc). 
THERAPEUTIC REGIMEN 
Patients who had been maintained on the same mutually 
agreed treatment for 3 months were regarded as being on 
satisfactory treatment. Treatment was divided into the 
following steps, using solely prophylactic medication: 
A Bronchodilator, including DSG; 
B Inhaled steroids, ‘800,~~g; 
C Inhaled steroids, 800~1000~g; 
D Inhaled steroids, > 1000 pg; 
E Oral steroids; 
U Unstable. 
Both PEF (Clement Clarke) and FEV, (Vitalograph, 
Maidenhead, UK) were measured at attendance. No 
specific instructions were given with regard to withholding 
bronchodilator before the attendance. Actual function 
was that recorded. Best function was established according 
to protocol (8), being the highest value recorded since 
1 January of the previous year: 
If actual function >80% predicted: after bronchodilator; 
If 70-80% predicted: on regular suppressive medication, 
with twice daily PEF recording for 2 5 days; 
If ~70% predicted: after 25 days of oral prednisolone 
(30 mglday) with twice daily recording of PEF. 
Actual and best function were expressed as per cent pre- 
dicted [Cotes (lo)] and actual/best function as a percentage. 
TABLE 4. The relationships between symptoms and parameters of pulmonary function as independent variables. 
The Spearman rank correlation coefficient and probabilities are shown (probability is 0.0001 except where shown) 
Actual 
PEF 
Best Actual/best Actual 
FEV, FVC 
Best Actual/best Best 
Bronchodilator usage 
Nocturnal disturbance 
Activity score 
0.38 0.33 0.24 0.39 0.36 0.12 0.28 
0 18 0.14 0.16 0.18 0.16 0.04 0.15 
(P=O.O002) (P=O 20) 
0.41 0.37 0.25 0.42 0.42 0.08 0.38 
(P=O.O2) 
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FIG. 2(a). Symptom scores (SEM) by quintile of pulmonary function: best. 
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FIG. 2(b). Symptom scores (SEM) by quintile of pulmonary function: actual/best. 
STATISTICAL METHODS Results 
The statistical methods used are either descriptive or are 
standard statistical methods. The methods used are 
reported as they occur in the Results section. All calcula- 
tions were performed using version 6.04 of SAS/PC. 
GENERAL 
The demographic details are shown sex-specifically in Table 
1 and pulmonary function in Table 2. Although mean best 
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FIG. 3. Symptom scores by quintile (Q) of actual/best 
FEV, stratified by best FEV,: (a) disturbed nights’; (b) 
bronchodilator usage2; (c) daily activity score3. Where 
‘Q5 vs Q4: x2=14.2, P=O.O002; Q5 vs 438~4: x2=9.3, 
P=O.O02; 2Q5 vs 44: x2=18 1, P=O.O0002; Q5 vs 438~4: 
x2=218, P<O.OOOOl; 3Q5 vs Q4: x2=30.0, P<O.OOOOl; Q5 
vs Q3&4: x2= 18.6, P =0.00002. Tests for trend applied 
throughout. 
PEF [male 86.3 (18.7), female 102.3 (+ 21.0)] is highly 
significantly greater in females than in males (PcO OOOl), 
actual/best FEV, [male 90.0 ( LL 11.6) female 89.3 ( + 11.6)] 
and actual/best PEF [male 87.4 (* 12.1), female 87.7 
( + 12.3)] were almost identical. Despite the differences in 
best function, the relationships between symptoms, func- 
tion and therapeutic step were similar in males and females, 
and so the combined results are presented. 
THERAPY 
The distribution of therapeutic step is summarized in Table 
3, the percentage distribution being shown for those on 
satisfactory maintenance treatment. Mean actual/best peak 
flow varied from 82% for those on oral steroids to 91% for 
those on low-dose inhaled corticosteroids. Of the total, 30 
(7.4%) males and 28 (6.7%) females were not on satisfactory 
maintenance treatment. 
SYMPTOMS 
The distribution of symptoms is shown in Fig. 1. Broncho- 
dilator usage was evenly distributed between virtually no 
use and more than 8 times a day. Only 22.5% of subjects 
had nocturnal disturbance; 16.6% had symptoms sufficient 
to disturb their normal activities and 20.7% claimed to cope 
despite symptoms. 
SYMPTOMS AND PULMONARY FUNCTION 
(RANK CORRELATION) 
There was a highly significant correlation between symp- 
toms score and actual function (Table 4). The relationship 
with best function was of the same order for all three 
measurements, but strongest with FEV,. The relationship 
between symptoms and actual/best function was much 
weaker for FEV,. With PEF the relationship with noctur- 
nal disturbance was similar for best and actual/best 
function. These results suggest that most of the associations 
of symptoms with pulmonary function can be explained by 
best function, particularly when the measure is FEV,. 
Disfvibufion of symptoms by quinfiles of pulmonary 
function 
The relationship between symptoms and pulmonary 
function was explored further by examining symptom mean 
scores within quintiles of pulmonary function. When symp- 
tom scores were plotted against best function, there was a 
consistent inverse relationship (Fig. 2(a)). In contrast symp- 
toms were highly significantly greater in the fifth quintile of 
actual/best FEV, than either the fourth taken alone, or the 
third and fourth taken together (see Fig. 2(b)). Although no 
such significant difference is seen between the fifth and 
lower quintiles of actual/best PEF, there is little difference 
in symptoms between the third, fourth and fifth quintiles, 
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E = Oral steroids 
U = Unstable 
2.5 2.5 
A B C D E U 
Nocturnal disturbance 
, 
A B C D E U 
FIG. 4. Symptom scores (SEM) for each treatment step. The size of a point is proportionate to the number of observations. 
Where SEM is not shown it is less than equal to the radius of the point. 
with a U-shaped trend for nocturnal disturbance and daily 
activity score (Fig. 2(b)). 
The relationship between symptoms and actual/best 
FEV, was then stratified by quintiles of best FEV,. Allow- 
ing for small numbers in some of the cells, the relationship 
between symptoms and actual/best function remains 
U-shaped, whatever the level of best function (Fig. 3). 
SYMPTOMS AND TREATMENT STEP 
Restricted activity and nocturnal disturbance increased 
progressively with symptoms step (Fig. 4). There was less 
variation with bronchodilator usage. The relation- 
ships between symptoms and actual/best function remains 
U-shaped whatever the level of therapy. This distribution is 
statistically highly significant (Fig. 5). 
Discussion 
All subjects included in this study were currently attending 
in secondary care when they first entered the Darlington 
and Northallerton long-term asthma study. However, some 
of the earlier entrants continued to attend hospital at long 
intervals solely because they had been enrolled. A further 
group consisted of special attenders, who had been specifi- 
cally recalled for the study. Although all these asthmatics 
were severe enough to be referred to hospital at one stage, 
the group as a whole included more patients with mild to 
moderate asthma than might be expected in a hospital- 
based study. They were, on the whole, well controlled, with 
mean actual/best function above the recommended 80-85% 
levels (1,2). The incidence of nocturnal disturbance is lower 
than that reported by Turner-Warwick (11). If the fre- 
quency of bronchodilator usage that requires adjustment of 
therapy is taken more than twice daily, then recorded 
bronchodilator usage was disappointing. Despite this, 
most subjects claimed little, if any, effect on their daily 
activity. 
Asthma was a clinical diagnosis supported by compatible 
reversibility of peak expiratory flow. Asthma and chronic 
obstructive pulmonary disease (COPD) were not regarded 
as mutually exclusive. Indeed, one of the purposes of the 
long-term study in which all these subjects participate is to 
investigate the development of COPD, as defined by best 
function, in an asthmatic population. We have previously 
observed that best function is more closely associated with 
therapeutic step than is actual/best. We hypothesized that 
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FIG. 5. Symptom scores by therapeutic step stratified by 
actual/best FEV,: (a) disturbed nights; (b) bronchodilator 
usage; (c) daily activity score. 
this would also apply to symptoms, but the contribution of 
actual/best function might be relatively much greater. The 
results confirm a highly significant relationship between the 
level of obstruction and symptoms observed at attendance. 
The strongest relationship was with restricted activity, 
followed by bronchodilator usage. The association with 
nocturnal disturbance was much weaker. All three esti- 
mates of best function (PEF, FEV, and FVC) showed 
similar relationships of the same magnitude and in the same 
order suggesting that best function is the principal determi- 
nant of symptoms. This is a striking observation consider- 
ing that if 85% of predicted is taken as the lower limit of 
normal, 50% of subjects did not show persistent obstruction 
as judged by FEV, and 70% as assessed by best PEF. This 
is in keeping with the finding that the association between 
mortality and best function observed in DANLAST is not 
restricted to those whose post bronchodilator function is 
outside the normal range. There is a close association 
between best function and therapeutic step (8) and we have 
now shown a similar association between symptoms and 
therapeutic step. 
It is clearly unrealistic to expect therapy to suppress 
symptoms below the level associated with best achievable 
function. Nevertheless, it was anticipated that there would 
be a relationship between actual/best function and symp- 
toms, independent of therapeutic step and best function. 
The target level for actual/best function (85%) was indepen- 
dent of actual/best function and the same at each therapeu- 
tic step. This reduces the chances of demonstrating a 
relationship between symptoms and actual/best function. In 
practice, median actual/best was above target in all but the 
high-dose inhaled and oral steps, representing only 22% of 
subjects. Provided that the fortieth centile was achieved 
there is no further advantage. Fewest symptoms were 
reported in those whose actual/FEV, at attendance was just 
below 100% of their best. During follow-up in our clinics, 
actual/best function is regarded as a measure of what the 
patient regards as satisfactory, rather than a diagnostic 
tool, so bronchodilator usage is not restricted before 
attendance. It follows that the recent use of rescue medica- 
tion by subjects symptomatic immediately before attend- 
ance is the most obvious explanation as to why those 
achieving near maximal function clinic had more symptoms 
than those at slightly lower levels. However, there are 
several other factors that might contribute to the U-shaped 
relationship between symptoms and actual/best function. 
Symptomatic patients on long-acting bronchodilators, 
particularly when used to control nocturnal disturbance, 
may have no reversible airflow obstruction at attendance, 
and so will appear to be well controlled. Other patients 
may have developed persistent obstruction which had 
become fixed, explaining why patients in the worst quintile 
of best function but in the best quintile of actual/best 
function tended to be particularly symptomatic. Sympto- 
matic patients with normal best and actual/best function 
may include those with sudden unpredictable but beta- 
agonist-reversible wheeze, and others whose expectations 
are unrealistically high. It is also possible that patients 
whose bronchial lability is not totally suppressed may 
eventually have least symptoms because of appropriate 
avoidance of sensitizers and non-specific irritants. In 
the longitudinal analyses of this study, in the 5- and IO-year 
periods up to 1993, the patients in the third quartile (range 
9695%) of actual/best function at entry had the lowest 
mortality (9,12). 
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It was confirmed that patients with most symptoms do 
have poorest actual/best function, but that a proportion of 
patients with acceptable actual/best function at attendance 
are also symptomatic. The results suggests that actual/best 
function of at least 85-90% is a useful check in those who 
claim to have good control, provided it is accepted that 
high values, particularly when approaching lOO%, will not 
exclude the possibility of important symptoms. In the 
longer term, the strong associations between symptoms and 
best function even within the normal range suggest that the 
benefit of present relieving therapy will always be limited, 
unless methods can be found to reverse currently irrevers- 
ible disease. Recent studies are beginning to suggest that 
early and appropriate use of inhaled corticosteroids may 
prevent its development (13,14). 
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